Trial NCT04899349

View at ClinicalTrials.gov 
Org. Study IDs: CBYL719C2202

Last trial update was posted on 2023-12-12

MeSH Interventions

Dapagliflozin Fulvestrant Metformin

MeSH Conditions

Breast Neoplasms

Other Conditions

Breast Cancer

Stopping Reasons

Study was early terminated due to slow recruitment and emerging data showing that prophylactic use of metformin may prevent or reduce the incidence of all-grades alpelisib-related hyperglycemia. The decision was not driven by safety concerns

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID